Active options: PFE MSTR PLTR NIO MSFT OXY DJT RIOT BA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Pfizer (PFE) PT Raised to $31 at CFRA
October 7, 2024 2:55 PM EDTCFRA analyst Sel Hardy raised the price target on Pfizer (NYSE: PFE) to $31.00 (from $30.00) while maintaining a Hold rating.
The analyst comments "We raise our target price to $31 from $30, 10.9x our 2025 EPS, below PFEs historical forward P/E average. We lift our 2024 EPS... More
